checkAd
    Startseite > Aktien > Candel Therapeutics > Nachrichten
    Candel Therapeutics Aktie
    7,8165
     
    USD
    -26,67 %
    -2,8435 USD
    Letzter Kurs 25.05.24 NYSE
    7,6500
     
    USD
    700 STK
    Geldkurs 24.05.24
    7,9200
     
    USD
    600 STK
    Briefkurs 24.05.24
    ISIN: US1374041093 · WKN: A3CVW2 · SYM: CADL · USA

    Neueste Nachrichten

    Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting
    23.05.24 · globenewswire · Candel Therapeutics
    Candel Therapeutics to Present at the Jefferies Global Healthcare Conference
    22.05.24 · globenewswire · Candel Therapeutics
    Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting
    20.05.24 · globenewswire · Candel Therapeutics
    Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
    14.05.24 · globenewswire · Candel Therapeutics
    Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
    25.04.24 · globenewswire · Candel Therapeutics
    Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
    11.04.24 · globenewswire · Candel Therapeutics
    Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
    09.04.24 · globenewswire · Candel Therapeutics
    Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
    04.04.24 · globenewswire · Candel Therapeutics
    Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma
    28.03.24 · globenewswire · Candel Therapeutics
    Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
    28.03.24 · globenewswire · Candel Therapeutics
    Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate
    05.03.24 · globenewswire · Candel Therapeutics
    CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma
    13.02.24 · globenewswire · Candel Therapeutics